Detalus Advisors LLC Grows Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Detalus Advisors LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 18.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,475 shares of the biopharmaceutical company’s stock after buying an additional 1,175 shares during the quarter. Detalus Advisors LLC’s holdings in Gilead Sciences were worth $444,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. FSB Premier Wealth Management Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at approximately $28,000. Joseph P. Lucia & Associates LLC acquired a new stake in Gilead Sciences in the 1st quarter valued at approximately $25,000. Capital Advisors Ltd. LLC increased its holdings in Gilead Sciences by 127.6% in the 4th quarter. Capital Advisors Ltd. LLC now owns 446 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 250 shares during the last quarter. TFO TDC LLC acquired a new position in shares of Gilead Sciences in the first quarter worth $27,000. Finally, Cornerstone Advisory LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth $34,000. 80.16% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:GILD opened at $62.22 on Wednesday. The company has a 50-day simple moving average of $61.98 and a 200-day simple moving average of $63.59. Gilead Sciences, Inc. has a one year low of $57.17 and a one year high of $74.12. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.30 and a current ratio of 1.48. The stock has a market capitalization of $78.04 billion, a price-to-earnings ratio of 17.41, a PEG ratio of 0.63 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.35. Gilead Sciences had a net margin of 16.43% and a return on equity of 44.98%. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.28 billion. During the same period in the prior year, the company earned $2.08 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. As a group, research analysts forecast that Gilead Sciences, Inc. will post 6.59 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, June 29th. Stockholders of record on Wednesday, June 15th were paid a dividend of $0.73 per share. The ex-dividend date of this dividend was Tuesday, June 14th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.69%. Gilead Sciences’s dividend payout ratio (DPR) is 81.56%.

Several research firms have commented on GILD. SVB Leerink began coverage on shares of Gilead Sciences in a research note on Monday, May 23rd. They issued a “market perform” rating and a $68.00 price target for the company. Piper Sandler lowered their target price on shares of Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating for the company in a research note on Monday, May 16th. TheStreet downgraded shares of Gilead Sciences from a “b-” rating to a “c+” rating in a research note on Friday, July 1st. StockNews.com initiated coverage on shares of Gilead Sciences in a research report on Thursday, March 31st. They issued a “buy” rating for the company. Finally, Royal Bank of Canada boosted their price target on shares of Gilead Sciences from $76.00 to $77.00 and gave the company an “outperform” rating in a research report on Tuesday, April 12th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $72.07.

Gilead Sciences Profile (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.